Opthea has discontinued development of sozinibercept in wet age-related macular degeneration, according to a press release.

LifeMine restructures with layoffs; PTC's Translarna is pulled in Europe; Opthea ends AMD trials; Apollomics and LaunXP make ...

Mach 7 and Universal Biosensors have announced their CEOs will depart, while changes at the top are likely at other biotechs.

Opthea said it agreed with the investors in its development funding agreement to end development of sozinibercept in wet AMD, and that the move wouldn't constitute a termination event under the ...

Following the negative results of the COAST Phase III trial announced on 24 March, Australia-based Opthea announced has updated on its clinical program, including the termination of COAST (Combination ...

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...

Opthea (OPT) announced updates on its Phase 3 clinical program, including the termination of COAST and accelerated topline results from its ...

The little hope left for Opthea shareholders has been crushed after the biotech said a second late-stage trial of its eye ...

Shares of Opthea Limited (NASDAQ:OPT – Get Free Report) have been assigned an average recommendation of “Hold” from the six ...

ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52Opthea and DFA ...

Welcome to the Trading Day blog for Monday, March 31. The ASX 200 index closed 1.7 per cent lower to 7843.40 points with all ...